Skip to content

Coupler Study.

PATENCY OF THE GEM MICROVASCULAR ANASTOMOTIC COUPLER SYSTEM™ IN CORONARY ARTERY BYPASS GRAFTING: A Pilot Study.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON20311
Enrollment
20
Registered
2013-03-21
Start date
2013-05-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cabg, total arterial revascularization

Interventions

Standard CABG procedure, with extended radial artery technique, with the radial-lita anastomoses facilitated with the GEM flow microvascular coupler.

Sponsors

Catharina Hospital Eindhoven. Sponsor: none
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Able to give informed consent able to understand the intent and clinical meaning of the study as well as its implication; 2. Patients between 18 years and 70 years old; 3. Willing and able to have follow-up visits and examinations; 4. Standard Euroscore < 2.

Exclusion criteria

Exclusion criteria: 1. Procedure is done as an emergency operation; 2. Unable to meet study requirements, i.e. mobility challenge; 3. Participation in any other clinical trial; 4. Pregnancy; 5. Concomitant with heart valve surgery; 6. History of any cardiac surgery other than PTCA and stent placement; 7. History of IABP within the last 30 days; 8. History of atrial fibrillation; 9. Congestive heart failure or been classified NYHA Class IV in the last 30 days; 10. History of bleeding disorder or history of thromboembolic disease requiring anticoagulation therapy; 11. Hemodynamically unstable; 12. History of acute or chronic dialysis; 13. Creatinine level of > 200 mmol/ml or 2,3 mg/dL in the last 30 days; 14. Documented or suspected acute systemic infection; 15. Need for immunosuppressive therapy; 16. Cerebrovascular accident within the last 2 weeks; 17. Allergy or other contraindication for aspirin or other anticoagulant/antiplatelet therapy; 18. Allergy or other contraindication for Iomeron® contrast agent; 19. Allergy or other contraindication for metoprolol.

Design outcomes

Primary

MeasureTime frame
1. Acute Patency: The presence of acute patency of the distal anastomoses as determined by flow measurements intraoperatively; 2. Chronic Patency: The presence of patency of the end-to-end radial-lita anastomoses as determined by multislice CT - Scan at 3 months; 3. Incidence of device related Adverse Events.

Contacts

Public ContactN.J. Verberkmoes

Michelangelolaan 2

nielsverberkmoes@hotmail.com+31 (0)40 2398680

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)